Article Details
Retrieved on: 2025-01-15 21:07:55
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The financing round is set to propel the advancement of the company's lead CD22 UB-VV400 programme in oncology and autoimmune clinical trials. Credit: ...
Article found on: www.pharmaceutical-technology.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here